Mankind Pharma to buy Bharat Serums in 13600 Crore
Mankind Pharma to Acquire Bharat Serums from Advent for Rs 13,630 Crore
On July 25, Mankind Pharma Limited announced that it has entered into a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines (BSV) Limited from private equity firm Advent International for an enterprise value of approximately Rs 13,630 crore, subject to closing adjustments.
"This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women's health and fertility drug market, alongside access to other high-entry-barrier products in critical care with established complex R&D tech platforms," Mankind said in a press release.
Key Developments Leading to the Official Announcement:
BSV, with over five decades of experience in biopharmaceuticals, offers a niche portfolio in women's health, covering the entire lifecycle from fertility to post-pregnancy.
"BSV’s acquisition represents a pivotal milestone in Mankind’s journey, establishing us as market leader in the Indian women’s health and fertility segment. We believe this segment has massive opportunities along with strong growth visibility globally, driven by structural tailwinds," said Rajeev Juneja, Vice-chairman and Managing Director, Mankind Pharma.
"We are proud to be one of the few Indian companies with several first-of-its-kind indigenously developed complex treatments that have delivered better patient outcomes. This acquisition reinforces our commitment to bringing cutting-edge products and expanding our reach to millions of patients in India and across the globe," said Sanjiv Navangul, CEO & Managing Director, BSV.
Shweta Jalan, Managing Partner and Head of Advent India, commented, "Mankind’s investment in BSV is a testament to our approach of identifying and nurturing unique businesses, working with high-quality management teams, and building these businesses into respected industry leaders. With the building blocks in place, we are confident that Mankind Pharma and BSV’s management team will continue their accelerated journey to build one of India’s largest pharma companies."
Moelis & Company acted as exclusive financial advisor and AZB & Partners acted as legal counsel to Mankind Pharma. Advent and BSV were advised by Jefferies LLC and J.P. Morgan as financial advisors and Khaitan & Co as legal counsel.
Mankind Pharma, Bharat Serums and Vaccines, BSV, Advent International, acquisition, women's health, fertility, biopharmaceuticals, critical care, R&D, India, pharma industry.
#MankindPharma #BharatSerums #AdventInternational #PharmaAcquisition #WomensHealth #Fertility #Biopharmaceuticals #CriticalCare #PharmaIndustry #IndiaPharma #HealthcareInnovation #pharmafund